CRISPR Therapeutics
CRSP · NASDAQ
Bulios Fair Price
$30.42
45.1% downside
Current Price
$55.43
According to Bulios Fair Price, CRSP is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
CRISPR Therapeutics AG is a Swiss biotechnology company specializing in the development of therapeutics based on the revolutionary CRISPR-Cas9 technology. This technology enables precise and efficient editing of genetic material, opening up new possibilities in treating genetic diseases and other conditions. CRISPR Therapeutics focuses its research on the treatment of various genetic disorders, including beta-thalassemia and muscular dystrophy. The company collaborates with renowned scientific institutions and experts to strengthen its research and develop new therapeutic approaches. CRISPR Therapeutics AG is an innovative player in the biotechnology industry and is committed to bringing revolutionary treatments to patients with genetic diseases. CRISPR Therapeutics AG (CRSP) shares represent an attractive investment opportunity for investors who follow the biotechnology sector and seek an innovative company engaged in treating genetic disorders.
Sector
Healthcare
Industry
Biotechnology
CEO
Samarth Kulkarni
Employees
393
Headquarters
Zug
Upcoming events
Earnings
Upcoming earnings report